| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | GPIV; GPVI; BDPLT11 |
| WB Predicted band size | 37 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human GP6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于GP6抗体的3篇参考文献概览(模拟生成，非真实文献)：
---
1. **文献名称**: *"Characterization of a novel monoclonal antibody against platelet glycoprotein VI with antithrombotic potential"*
**作者**: Al-Tamimi, M., et al.
**摘要**: 该研究报道了一种新型单克隆抗体(mAb)对血小板糖蛋白GP6的靶向作用，通过体外实验证明其能抑制胶原诱导的血小板聚集，并在小鼠模型中显著减少动脉血栓形成，同时未增加出血风险，提示其作为抗血栓治疗药物的潜力。
2. **文献名称**: *"Autoantibodies to GPVI in immune thrombocytopenia: prevalence and functional significance"*
**作者**: Joutsi-Korhonen, L., et al.
**摘要**: 研究分析了免疫性血小板减少症(ITP)患者中GP6自身抗体的存在及其临床意义，发现约15%的患者血清中检测到抗GP6抗体，这些抗体可通过阻断胶原结合导致血小板功能异常，提示其参与ITP的病理机制。
3. **文献名称**: *"Targeting GPVI with a humanized antibody for safe and effective thromboprotection in primates"*
**作者**: Bültmann, A., et al.
**摘要**: 该文献描述了一种人源化GP6抗体的开发，通过在灵长类动物模型中的实验，证明其能有效抑制血栓形成且不干扰正常止血功能，为临床转化提供了安全性及有效性的 preclinical 证据。
---
注：上述文献为示例性内容，实际研究中请通过PubMed、Web of Science等数据库检索真实文献。
The GP6 antibody targets glycoprotein VI (GPVI), a critical collagen receptor expressed on platelet surfaces. GPVI plays a central role in platelet activation and thrombus formation by binding to exposed collagen at sites of vascular injury, initiating signaling cascades that promote platelet adhesion, aggregation, and clot stabilization. Structurally, GPVI is a member of the immunoglobulin superfamily, coupled with the Fc receptor γ-chain (FcRγ) to form a signaling complex. Its activation triggers intracellular pathways involving Syk and PLCγ2. ultimately leading to thrombus formation.
GPVI has garnered attention as a therapeutic target due to its specific role in pathological thrombosis while minimally impacting physiological hemostasis. Antibodies against GPVI, such as the monoclonal antibody 9O12. have been explored to inhibit platelet-collagen interactions, offering potential for safer antithrombotic therapies with reduced bleeding risks compared to conventional antiplatelet drugs. Research also highlights GPVI's involvement in inflammatory conditions like rheumatoid arthritis and atherosclerosis, broadening its clinical relevance.
However, GPVI deficiency or polymorphisms in humans (e.g., GPVI mutations) are linked to mild bleeding tendencies, underscoring its balanced role in hemostasis. Current studies focus on optimizing GPVI-targeting biologics, including antibody fragments and fusion proteins, to enhance efficacy and safety. These advancements position GPVI antibodies as promising tools for both understanding thrombotic mechanisms and developing targeted therapies.
×
